• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴西炎症性肠病患者选择治疗方法的偏好因素。

FACTORS ASSOCIATED WITH PATIENT´S PREFERENCE IN CHOOSING THEIR THERAPY FOR INFLAMMATORY BOWEL DISEASE IN BRAZIL.

机构信息

Universidade Estadual Paulista (Unesp), Faculdade de Medicina, Departamento de Clínica Médica, Botucatu, SP, Brasil.

IBD Unit, St Mark's Hospital, London, United Kingdom.

出版信息

Arq Gastroenterol. 2020 Sep-Dec;57(4):491-497. doi: 10.1590/S0004-2803.202000000-86.

DOI:10.1590/S0004-2803.202000000-86
PMID:33331482
Abstract

OBJECTIVE

This study aims to evaluate patient's preferences in the choice of their therapy and the factors that influence this choice.

METHODS

This cross-sectional study enrolled 101 outpatients with Crohn's disease or ulcerative colitis. The inclusion criteria were age ≥18 years and no previous exposure to biological therapy. Patients' preferences were assessed through questions that addressed the preferred mode of administration (oral, subcutaneous, or intravenous) and the factors that determined the choice of medication (efficacy, medical indication, fear of medication, convenience, mode of application, and personal doctors' indication).

RESULTS

The mean age was 43.6±13.5 years, 75.3% were female, and 81.2% were cases of ulcerative colitis. Regarding the mode of administration, the majority of patients preferred oral (87.1%), followed by intravenous (6.93%) and subcutaneous (5.94%) medications. The reasons were "I prefer to take it at home" (42.57%), "I have more freedom" (36.63%), "I don't like self-application" (29.70%), and "I believe it works better" (19.80%). Younger patients and patients in clinical disease activity preferred intravenous mode compared to the oral route (P<0.05). Doctor's opinion (98%) was an important factor associated with the medication choice.

CONCLUSION

Oral route was the preferred mode of administration and most patients took their physician's opinion into account in their choice of medication.

摘要

目的

本研究旨在评估患者在治疗选择方面的偏好以及影响这种选择的因素。

方法

这项横断面研究纳入了 101 例克罗恩病或溃疡性结肠炎门诊患者。纳入标准为年龄≥18 岁且以前未接受过生物治疗。通过询问患者首选的给药方式(口服、皮下或静脉)以及决定药物选择的因素(疗效、医学指征、对药物的恐惧、便利性、给药方式和医生的建议)来评估患者的偏好。

结果

患者的平均年龄为 43.6±13.5 岁,75.3%为女性,81.2%为溃疡性结肠炎患者。关于给药方式,大多数患者首选口服(87.1%),其次是静脉(6.93%)和皮下(5.94%)给药。原因是“我更喜欢在家服用”(42.57%)、“我更自由”(36.63%)、“我不喜欢自行给药”(29.70%)和“我相信它效果更好”(19.80%)。与口服途径相比,年轻患者和临床疾病活动患者更倾向于静脉途径(P<0.05)。医生的意见(98%)是与药物选择相关的重要因素。

结论

口服途径是首选的给药方式,大多数患者在选择药物时会考虑医生的意见。

相似文献

1
FACTORS ASSOCIATED WITH PATIENT´S PREFERENCE IN CHOOSING THEIR THERAPY FOR INFLAMMATORY BOWEL DISEASE IN BRAZIL.巴西炎症性肠病患者选择治疗方法的偏好因素。
Arq Gastroenterol. 2020 Sep-Dec;57(4):491-497. doi: 10.1590/S0004-2803.202000000-86.
2
Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration.炎症性肠病(IBD)患者更喜欢口服片剂,而不是其他给药方式。
Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):1091-1096. doi: 10.1080/17474124.2021.1898944. Epub 2021 Mar 10.
3
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients.炎症性肠病患者从静脉注射生物疗法转换为皮下生物疗法:一项患者在线调查
Indian J Gastroenterol. 2024 Feb;43(1):215-225. doi: 10.1007/s12664-023-01500-2. Epub 2024 Jan 20.
4
Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.优化炎症性肠病生物制剂的选择:使用联合分析开发在线患者决策辅助工具。
Am J Gastroenterol. 2018 Jan;113(1):58-71. doi: 10.1038/ajg.2017.470. Epub 2017 Dec 5.
5
[What are the reasons for patient preference? A comparison between oral and subcutaneous administration].[患者偏好的原因是什么?口服给药与皮下给药的比较]
Z Orthop Unfall. 2012 Sep;150(4):397-403. doi: 10.1055/s-0031-1298347. Epub 2012 Mar 15.
6
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.医生应为炎症性肠病患者的抗TNF治疗提供共同决策。
J Korean Med Sci. 2017 Jan;32(1):85-94. doi: 10.3346/jkms.2017.32.1.85.
7
Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).韩国克罗恩病患者在选择抗肿瘤坏死因子药物时的偏好影响因素(CHOICE研究)
Gut Liver. 2016 May 23;10(3):391-8. doi: 10.5009/gnl15126.
8
Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.预测生物治疗的前瞻性讨论:炎症性肠病患者及其处方医生的开放性和偏好调查结果
Adv Ther. 2017 Jun;34(6):1398-1410. doi: 10.1007/s12325-017-0545-4. Epub 2017 May 8.
9
Inflammatory Bowel Disease Patients' Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study.炎症性肠病患者对皮下和静脉治疗的偏好:一项混合方法研究。
Dig Dis. 2023;41(3):412-421. doi: 10.1159/000528586. Epub 2022 Dec 7.
10
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study.炎症性肠病患者治疗维持方案的比较可接受性:全国性ACCEPT2研究结果
Inflamm Bowel Dis. 2023 Apr 3;29(4):579-588. doi: 10.1093/ibd/izac119.

引用本文的文献

1
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.炎症性肠病患者对治疗属性的偏好:一项在七个欧洲国家进行的使用离散选择实验的大型调查结果
Inflamm Bowel Dis. 2024 Dec 5;30(12):2380-2394. doi: 10.1093/ibd/izae015.
2
Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.慢性免疫系统疾病治疗中皮下注射与静脉注射给药的患者偏好:一项系统评价
Patient Prefer Adherence. 2021 Apr 19;15:811-834. doi: 10.2147/PPA.S303279. eCollection 2021.